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Abstract
Background: Aprotinin for reducing blood loss during coronary artery bypass surgery was
withdrawn from the market after early termination of a large randomised controlled trial (RCT)
showing excess mortality for patients receiving aprotinin compared to lysine analogues. Several
meta-analyses of small RCTs did not show excess mortality and even indicated reduced mortality,
while several observational studies showed excess mortality. The aim of this paper is to review the
quality of the meta-analysis of a Cochrane report.
Methods: The 52 studies included in the meta-analysis of the Cochrane report were reviewed
according to whether an objective to study mortality was formulated in advance, whether follow-
up method or time were specified, and whether the study had statistical power to show any effect.
Results: The Cochrane report restricted the analysis to RCTs, but the largest study should not
have been included given that it was a prospective observational study with 1 784 patients rather
than an RCT. None of the RCTs had sufficient statistical power to detect differences in mortality.
Most studies had fewer than 100 patients. Seven out of 51 RCTs had mortality outcome as one of
their objectives. Only very few described follow-up method or time.
Conclusion: It is doubtful whether small studies should be included in meta-analyses if they do not
have the purpose of studying the specified outcome and if the follow-up method or time are not
adequately described. The aprotinin saga shows overconfidence in small RCTs of inferior quality
compared to well-conducted observational studies.
Background
Aprotinin to reduce blood loss during coronary artery
bypass surgery was approved by the U.S. Food and Drug
Administration (FDA) in 1993 and has been a very com-
mon procedure since then. The BART study, which was
recently published in the New England Journal of Medicine
[1], showed that aprotinin for reducing blood loss during
coronary artery bypass surgery increased mortality by 50
percent (RR = 1.53; 95% CI, 1.06–2.22) compared with
groups receiving lysine analogues. Before BART, several
meta-analyses of randomised controlled trials (RCTs) had
shown no indication of an excess risk of death or had even
shown a reduced risk [2-4], while several observational
studies had shown excess mortality risks and increased
risk of renal dysfunction [5-9]. The reasons for these dis-
crepancies deserve further analysis.
The focus of the meta-analyses was usually aprotinin's
ability to reduce blood loss during surgery. Aprotinin has
been a successful treatment in this connection. Based on a
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Lancet even claimed that many of the later studies were
unnecessary since meta-analysis showed that the effects
had already been established after the twelfth trial in 1992
[10]. This was probably true with respect to blood loss,
but not with respect to mortality and other adverse effects.
Blood loss is also primarily a surrogate endpoint.
The findings of the observational studies by Mangano
[6,7], Schneeweiss [8] and Shaw [9] were based on pro-
spective cohorts of 4 374, 78 199 and 10 275 patients
respectively. They all showed statistically significant mor-
tality odds ratios. The study by Mangano [6], which had
an odds ratio of 1.48 (95% CI, 1.19–1.85), controlled for
background characteristics such as age, gender, socioeco-
nomic status, geographic region and medical history. The
study by Schneeweiss [8] showed an odds ratio of 1.64
(95% CI, 1.50–1.78) adjusted for 41 background charac-
teristics. Both of these studies showed a dose-response
relationship, with higher mortality for higher doses of
aprotinin. A case-control study by Karkouti et al used pro-
pensity scores and did not find any differences in adverse
outcomes except for renal dysfunction, which was signifi-
cantly higher in the aprotinin group [5].
The observational studies of aprotinin, which were much
larger than the RCTs, controlled for many important back-
ground characteristics of the patients. The critics of these
observational studies emphasised the limitations of
observational studies in general, as well as uncertainty
about whether all confounders had been controlled for.
Selection bias may also have been present due to the fact
that aprotinin was a preferred choice for patients with
high risk of bleeding. These factors were probably among
the main reasons that FDA did not take more forceful
action between 2006 and late 2007.
One of the main purposes of meta-analysis is to summa-
rise data from small studies to obtain more robust esti-
mates of effects. However, this is appropriate only if the
small RCTs are well-designed and well-conducted. In
order to analyse whether this was the case, this author
examined all the studies in one of the meta-analyses
according to certain quality criteria. The meta-analysis
chosen was a 2007 Cochrane report that reviewed anti-
fibrinolytic use for minimising perioperative allogenic
blood transfusion [2]. The report included assessments of
both the benefits and the risks of aprotinin versus placebo
or other treatment options. The review restricted the anal-
ysis to RCTs and referred to observational studies in the
discussion section only.
Mortality was assessed in the Cochrane report by perform-
ing a meta-analysis of 52 small RCTs. The meta-analysis
showed no excess risk for aprotinin versus placebo (RR =
0.90, 95% CI, 0.67–1.20 with a total of 7 721 patients and
192 deaths).
Methods
All 52 studies were analysed in full text. The three ques-
tions raised were: Was mortality stated as an objective?
Did the study have power to analyse adverse mortality
effects? Was the method for follow-up clearly described? If
mortality was stated as an objective and if statistical power
was considered, it is an indication that the investigators
intended to examine mortality thoroughly. A description
of the follow-up method is very important if the reader is
to have confidence in the results.
Results
The 52 studies were assessed by analysing the formulated
objectives, the specified follow-up method and time, and
potential power to detect differences in mortality (Table
1). The largest study should not have been included given
that it was a prospective observational study with 1 784
patients rather than an RCT. Most studies had fewer than
100 patients. Seven out of 51 (13.7%) RCTs had mortality
outcome as one of the objectives. None of the studies had
sufficient statistical power to detect differences in mortal-
ity. Only very few described the follow-up method. Fol-
low-up time was specified in 16 out of 51 (31.4%) studies
and varied from 24 hours, during hospitalisation, to 30
days to 3 months. Most studies did not show whether
mortality was measured during surgery, hospital stay or
longer follow-up periods.
Discussion
The analysis was restricted to RCTs, but the largest of the
52 included studies was an observational study by Diet-
rich et al [11] and was therefore erroneously included in
the meta-analysis. This study was conducted was con-
ducted before the FDA approval in 1993 when there was
no suspicion of adverse effects. This is apparent from the
study design with no focus on mortality and no control
for confounding factors. Analysis of all the included RCTs
in the Cochrane review of mortality showed that a minor-
ity of the studies had mortality outcome as one of their
objectives. Nor did any of the studies have statistical
power to detect differences in mortality. This clearly indi-
cates the investigators' lack of focus on mortality and
adverse events. However, this does not mean a priori that
the studies lacked quality, although it does indicate that
less time was spent on this part of the study design.
The fact that most studies completely lacked a description
and specification of follow-up method or time should
raise more serious concerns. Many studies did not specify
whether deaths occurred during surgery, during hospital
stay or within a specified period of time. It is questionable
whether it is appropriate to perform a meta-analysis withPage 2 of 7
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Reference, author Adverse-mortality effects 
formulated as an outcome 
in the objective
Included patients [N] and design or power to 
analyse adverse mortality effects
N
Method and follow-up 
period for studying 
adverse mortality effects
Alvarez, 1995 No 100 No Not specified
Bidstrup, 1989 No 80 No Not specified
Bidstrup, 1993 No 90 No Not specified, 7–12 days
Blauhut, 1994 No 43 No Not specified
Casas, 1995 No 149 No Not specified
Cosgrove, 1992 No 169 No Not specified
D'Ambra, 1996 Yes 212 No Yes, hospitalisation
Dietrich, 1992 Yes, but no RCT 1784 Yes Yes, hospitalization
Dietrich, 1995 No 30 No Not stated, at least 41 days
Ehrlich, 1998 No 50 No Not stated, at least 30 days
Garcia-Huete, 1997 No 80 No Not stated, at least 30 days
Green, 1995 Yes 84 No Yes, 3 months after discharge.
Hardy, 1993 No 41 No Not specified
Hayashida, 1997 Yes 167 No Not stated, at least 12 days
Jamieson, 1997 No 91 No Not specified
Lab, 1995 No 110 No Yes, hospitalisation
Lemmer, 1996 Yes 704 No Not stated
Lemmer, 1994 Yes 216 No Yes, 30 days mortality
Levy, 1995 Yes 287 No Not specified
Liu, 1993 No 40 No Not specified
Maccario, 1994 [It] No 99 No Not stated
Mohr, 1992 No 50 No Not specified
Okita, 1996 No 112 No Not specified
Rocha, 1994 No 109 No Yes, first 10 days
Royston, 1987 No 22 No Not specified
Stammers, 1997 No 20 No Yes, hospitalisation
Swart, 1994 Yes 100 No Yes, 7 days after surgeryPage 3 of 7
(page number not for citation purposes)
BMC Health Services Research 2009, 9:34 http://www.biomedcentral.com/1472-6963/9/34very different follow-up times or when most of the studies
did not specify follow-up time at all. Mortality is not an
adverse effect that occurs during hospitalisation only.
Severe complications may lead to death long after dis-
charge from hospital. For example, thrombotic events can
manifest clinically over a period of months or years fol-
lowing arterial occlusion [12,13]. In order to properly
analyse mortality, follow-up time must be specified.
Ashrat, 1997 No 38 No Not stated
Alderman, 1998 No 870 No Yes, hospitalisation
Bidstrup, 2000 No 60 No Not specified, 15 days 
reported
Cohen, 1998 Yes, maybe 115 No Not specified
Misfeld, 1998 No 42 No Not specified, hospitalisation
Nuttall, 2000 No 168 No Not specified, 24 hours
Schweizer, 2000 No 57 No Not specified
Moran, 2000 No 42 No Yes, 3 months
Murkin, 2000 No 298 No Yes, 3 months
Alvarez, 2001 No 55 No Not specified
Dignan, 2001 No 202 No Not specified
Findlay, 2001 No 63 No Yes, hospitalisation
Kyriss, 2001 No 38 No Not specified
Golanski, 2000 No 54 No Not specified
Palmer, 2003 No 100 No Yes, 3 months
Englberger, 2002a No 29 No Yes, hospitalisation
Englberger, 2002b No 47 No Yes, hospitalisation
Kipfer, 2003 No 30 No Not specified
Rodrigus, 1996 No 93 No Not specified
Kuepper, 2003 No 120 No Yes, 24 hours after surgery
Van der Linden, 2005 No 75 No Probably 30 days
Kunt, 2005 No 86 No Probably 1 day, operative 
deaths
Koster, 2004 No 200 No Yes, during hospitalisation
Diprose, 2005 No 198 No Not stated
Kuitunen, 2005 No 60 No Not stated
Footnote: The complete references can be found in the Cochrane review by Henry DA et al.[2].
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debate concerning the value of large versus small trials.
Previous studies have suggested that publication bias is
one reason for discrepancies between the results of large
RCTs and meta-analyses of small RCTs [14-16]. Kjaergard
et al [17] focused on methodological quality and con-
cluded that inadequate generation of the allocation
sequence, allocation concealment and double blinding
lead to exaggerated estimates of benefits and may contrib-
ute to discrepancies between the results of large RCTs and
meta-analyses of small RCTs. In general, it seems likely
that large studies requiring more resources and funds have
undergone a more thorough review process than small
studies. The results of the present paper also indicate the
need to analyse the quality of studies before including
them in a meta-analysis. Studies cannot be included if the
method of following up outcome has not been specified.
Already before the publication of the BART study, an edi-
torial in the New England Journal of Medicine discussed the
limitations of these small trials and argued that they
should have been interpreted more cautiously, particu-
larly given the contradictory findings of some epidemio-
logical studies [18].
Another issue raised by the aprotinin saga is the value of
observational studies in examining rare and adverse out-
comes such as mortality. The advantages of large, well-
conducted RCTs are undisputable. But even large RCTs
rarely have the ability to show significant results concern-
ing rare outcomes and usually have short follow-up peri-
ods. In the case of aprotinin, data from several well-
conducted and very large observational studies were avail-
able between 2006 and late 2007 without any major
action being taken. Two of the studies also showed a dose-
response relationship, with higher mortality odds ratios
for higher doses of aprotinin [7,8] A 2006 case-control
study and a 2007 meta-analysis of RCTs showed that high-
dose aprotinin significantly increased the risk of renal dys-
function [19]. The main reasons for not taking action
seem to be confidence in small RCTs that did not show
any adverse effects and mistrust of observational studies
that showed excess mortality. In this case, the consistent
findings of the observational studies should have been
more carefully considered, especially when other meas-
ures to reduce bleeding were available. In retrospect, it
seems clear that aprotinin would have been withdrawn
from the market by the company earlier if FDA and others
had taken well-conducted observational studies more
seriously.
Conclusion
The RCTs included in the Cochrane review had blood loss
as the main outcome and were not suitable for studying
mortality. Methods were not well-specified and had seri-
ous limitations. In such cases, meta-analysis is a question-
able approach, considering the methodological
limitations of such small trials.
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Professor Måns Rosén raises concerns about our 2007
Cochrane review of anti-fibrinolytic drugs [2]. The topic is
an important one – many patients receive these drugs as
an adjunct to reduce blood loss during a variety of surgical
procedures. Some of his concerns go to the heart of
assumptions that are made when conducting meta-analy-
ses of randomized controlled clinical trials.
First, we should point out that we have updated some of
the meta-analyses of trials contained in the Cochrane
review and have recently published the results. This anal-
ysis is confined to the use of anti-fibrinolytic trials in car-
diac surgery. The full text is available at [20]. In the
updated report we found an increased risk of death in sub-
jects treated with aprotinin compared with tranexamic
acid or aminocaproic acid. Our conclusions were "The risk
of death tended to be consistently higher with use of apro-
tinin than with use of lysine analogues. Aprotinin had no
clear advantages to offset these harms...The conclusions of
our updated review conflict with those of our published
Cochrane review.... The addition of data from the large
BART study increased the relative risk of death with the
use of aprotinin compared with the use of either tran-
examic acid or epsilon aminocaproic acid."
So, the updated review is consistent with the observa-
tional studies of aprotinin (recently presented in a system-
atic review [21]) in finding an increased risk of death with
aprotinin compared with the lysine anti-fibrinolytic
agents. But significantly, the updated meta-analysis found
no increase in the risk of death with aprotinin compared
with placebo/no treatment when used in cardiac surgery
(summary RR for death 0.93; 95% CI 0.69, 1.25). This
summary analysis comprised results from forty-nine trials
of aprotinin, which included 7439 participants and
reported on 182 deaths. This finding troubles Professor
Rosén as it is at odds with the results of large observa-
tional studies and is based on small randomized trials that
were not designed to show a change in the incidence ofPage 5 of 7
(page number not for citation purposes)
BMC Health Services Research 2009, 9:34 http://www.biomedcentral.com/1472-6963/9/34death or indeed cardiovascular events. It should be noted
here that neither was the BART study.
The five main criticisms made by Rosén are: that few of the
trials had mortality as a stated outcome; none of the trials
had statistical power to detect differences in mortality;
very few trials described the follow-up methods and fol-
low-up time was not specified in most of them; follow-up
may have been too short to quantify late deaths. One large
study was not a randomized trial. While we don't dispute
the accuracy of these observations about the individual
studies we disagree with the inferences that Professor
Rosén makes regarding the systematic review.
If at least one large trial had specified thrombosis (a theo-
retical adverse effect of these drugs) and death as out-
comes, and had adequate power and sufficient follow-up,
there would have been little need for the meta-analysis.
One of the purposes of systematic reviews is to examine
events that were not primary outcomes of the individual
trials. By denying this Rosén is arguing against a central
purpose of systematic reviews. In terms of patient follow-
up, this varied between the aprotinin trials, but should
not have varied between the treatment and control arms
of the individual trials. In other words, it is unlikely that
this was a source of bias either toward or away from the
null. While some non-fatal events could lead to late mor-
tality, we found no increase in the risk of non-fatal throm-
bosis. In addition, the BART trial3, cited by Rosén, found
a separation of survival curves early in the post-operative
phase and the curves are roughly parallel from Day 10
onwards. So, it is unlikely that undetected late mortality
accounts for the lack of risk that we found in the meta-
analysis of the placebo/inactive controlled aprotinin tri-
als.
However, we do share one of Rosén's worries, which have
also been expressed by Ray [22]. This concerns the com-
pleteness of reporting of uncommon events in small clin-
ical trials. We put considerable effort into identifying trials
that appeared to report mortality, but we have no way of
assessing how rigorously this was done. One concern
about trials of drugs is the tradition to report 'adverse reac-
tions' – events that are reported as 'possibly' or 'probably'
caused by the drug. The use of causality assessment, tradi-
tional in the assessment of voluntary adverse reaction
reports, could lead to under-reporting of events. This
process has no place in the reporting of the results of clin-
ical trials.
Regarding the alleged inclusion of one non-randomized
study in the meta-analysis, the methods section in this
study states: "Patients were randomly assigned to either an
aprotinin treatment group (group A) or to a control group
without aprotinin (group C)". We accepted this informa-
tion in good faith, but scored the methodological quality
of the study as low. We did not routinely contact study
authors to confirm the details of randomization. Like
most meta-analysts we accepted and scored the written
description of the methods. We subsequently contacted
the senior author, Professor Wulf Dietrich of the Univer-
sity of Munich, who kindly reviewed his files (the study
was reported in 1992 [11]) and has advised us that in his
opinion the study does not meet contemporary standards
for being considered 'randomized', that there was a possi-
bility of selection bias, but this would have led to sicker
patients receiving aprotinin. It should be noted that exclu-
sion of this study does not change the overall estimate of
mortality with aprotinin compared with control: Pooled
RR = 1.02 (95%CI 0.71 to 1.47).
So did our Cochrane review miss an adverse effect of apro-
tinin? That is possible. Are there significant problems with
meta-analyses of infrequent outcomes measured in small
clinical trials? Yes there are. But in our view the major crit-
icisms voiced by Professor Rosén concerning the specifica-
tion of outcomes, statistical power of individual studies
and variable follow up of trial participants are not the key
issues. Under-reporting of infrequent events is pivotal and
if non-differential (the most likely scenario) will lead to a
bias to the null. This could account for the fact that we
found no increase in mortality in the aprotinin trials. We
have acknowledged this in the updated review.3 Despite
considerable methodological improvements, meta-analy-
sis remains an imperfect science, being an observational
not an experimental discipline, which relies heavily on
the diligence of trial investigators and authors of reports.
Systematic reviews must be rigorously performed, but
Professor Rosén has not made a comprehensive assess-
ment of the quality of our work. Tools exist to enable
appraisal of systematic reviews (for instance the recently
validated AMSTAR instrument) [23]. Systematic reviews
have value in summarizing literature, providing overall
estimates of effect and in assisting in the planning of clin-
ical trials. In the latter regard it is significant that two of
the authors of the Cochrane review (Fergusson and Laupa-
cis [1]) were involved in the planning conduct and moni-
toring of the BART trial. This trial owed a lot to the results
of the many published meta-analyses of this literature.
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